Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 13/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 13/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14651915 | 0.85 | NTRK1 (0.38) | CSNK2A2CSNK2A1NTRK1PIK3CDNTRK2 | |
| SCHEMBL21199390 | 0.84 | CSNK2A2 (0.40) | CSNK2A2CSNK2A1NTRK1PIK3CDNTRK2 | |
| SCHEMBL28508014 | 0.84 | NTRK1 (0.38) | CSNK2A2CSNK2A1NTRK1PIK3CDNTRK2 | |
| SCHEMBL12537596 | 0.80 | NTRK1 (0.41) | CSNK2A2CSNK2A1NTRK1PIK3CDNTRK2 | |
| SCHEMBL12285417 | 0.77 | KDM4E (0.45) | CSNK2A2CSNK2A1 | |
| SCHEMBL19279752 | 0.76 | CSNK2A2 (0.35) | CSNK2A2CSNK2A1NTRK1PIK3CDNTRK2 | |
| SCHEMBL19280638 | 0.75 | CSNK2A2 (0.38) | CSNK2A2CSNK2A1NTRK1 | |
| SCHEMBL21199542 | 0.75 | CSNK2A2 (0.43) | CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL12537481 | 0.75 | NTRK1 (0.51) | CSNK2A2CSNK2A1NTRK1PIK3CDNTRK2 | |
| SCHEMBL19710827 | 0.75 | CSNK2A2 (0.34) | CSNK2A2CSNK2A1NTRK1PIK3CDNTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | CSNK2A2 842/4885CSNK2A1 862/4885NTRK1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.